From DCAT Value Chain Insights (VCI)
EMD Serono, the US biopharmaceuticals subsidiary of Merck KGaA, Darmstadt, Germany has appointed Frederick E. Munschauer to Vice President of Medical Affairs, Neurology and Immunology. In this capacity, he will lead the medical affairs activities for clinical, commercial and business development projects and collaborations for Rebif® (interferon beta-1a) as well as the company’s Immunology and Neurology pipeline. Dr. Munschauer joins EMD Serono from Biogen, bringing more than 30 years of knowledge in the area of neurology, specifically multiple sclerosis.
Source: Merck KGaA
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription